GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (OTCPK:ATHJF) » Definitions » Debt-to-Asset

Percheron Therapeutics (Percheron Therapeutics) Debt-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Percheron Therapeutics Debt-to-Asset?

Percheron Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.01 Mil. Percheron Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Percheron Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $13.37 Mil. Percheron Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.00.


Percheron Therapeutics Debt-to-Asset Historical Data

The historical data trend for Percheron Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics Debt-to-Asset Chart

Percheron Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 0.04 0.01 0.01

Percheron Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 -

Competitive Comparison of Percheron Therapeutics's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Percheron Therapeutics's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Percheron Therapeutics's Debt-to-Asset falls into.



Percheron Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Percheron Therapeutics's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Percheron Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Percheron Therapeutics  (OTCPK:ATHJF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Percheron Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Percheron Therapeutics (Percheron Therapeutics) Business Description

Traded in Other Exchanges
Address
14 Wallace Avenue, Toorak, VIC, AUS, 3142
Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals. The company operates in two segments that have been identified based on its antisense oligonucleotide products as ATL1102 and ATL1103.